Design and discovery of 4-anilinoquinazoline ureas as multikinase inhibitors targeting BRAF, VEGFR-2 and EGFR
- 1 May 2013
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 4 (6) , 979-986
Abstract
4-Anilinoquinazoline ureas were envisaged according to the hybrid-design approach based upon two privileged pharmacophores in kinase drug discovery, i.e. 4-anilinoquinazoline and unsymmetrical diaryl urea. In our structure–activity relationships (SAR) campaign, title compounds were synthesized and profiled in biochemical assay for their kinase inhibitory activity. Title compounds 18–20 were found to be multikinase inhibitors with profound activity against BRAF, BRAF V600E, VEGFR-2 and EGFR. Molecular docking into DFG-out conformations of BRAF and VEGFR-2 suggested that they might be type II inhibitors.Keywords
This publication has 25 references indexed in Scilit:
- Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitorsProceedings of the National Academy of Sciences, 2012
- Impact of aryloxy-linked quinazolines: A novel series of selective VEGFR-2 receptor tyrosine kinase inhibitorsBioorganic & Medicinal Chemistry Letters, 2011
- [4-(6,7-Disubstituted quinazolin-4-ylamino)phenyl] carbamic acid esters: a novel series of dual EGFR/VEGFR-2 tyrosine kinase inhibitorsMedChemComm, 2010
- Design, Synthesis, and DNA-Binding of N-Alkyl(anilino)quinazoline DerivativesJournal of Medicinal Chemistry, 2010
- Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancerJournal of Enzyme Inhibition and Medicinal Chemistry, 2010
- Selectively Nonselective Kinase Inhibition: Striking the Right BalanceJournal of Medicinal Chemistry, 2009
- High-Throughput Biochemical Kinase Selectivity Assays: Panel Development and Screening ApplicationsSLAS Discovery, 2009
- Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibitionCellular Signalling, 2007
- Discovery of Novel Benzimidazoles as Potent Inhibitors of TIE-2 and VEGFR-2 Tyrosine Kinase ReceptorsJournal of Medicinal Chemistry, 2007
- Patterns of somatic mutation in human cancer genomesNature, 2007